Literature DB >> 31048799

Long path to MYC inhibition approaches clinical trials.

M Teresa Villanueva.   

Abstract

Entities:  

Keywords:  Biotechnology; Cancer; Drug discovery

Year:  2019        PMID： 31048799     DOI： 10.1038/d41573-019-00055-2

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  Dual Inhibition of Myc Transcription and PI3K Activity Effectively Targets Colorectal Cancer Stem Cells.

Authors:  Miriam Gaggianesi; Laura Rosa Mangiapane; Chiara Modica; Vincenzo Davide Pantina; Gaetana Porcelli; Simone Di Franco; Melania Lo Iacono; Caterina D'Accardo; Francesco Verona; Irene Pillitteri; Alice Turdo; Veronica Veschi; Ornella Roberta Brancato; Giampaolo Muratore; Giuseppe Pistone; Maria Rita Bongiorno; Matilde Todaro; Ruggero De Maria; Giorgio Stassi
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

2.  The c-Myc/AKT1/TBX3 Axis Is Important to Target in the Treatment of Embryonal Rhabdomyosarcoma.

Authors:  Danica Sims; Hapiloe Mabaruti Maranyane; Victoria Damerell; Dhirendra Govender; Ashwin W Isaacs; Jade Peres; Sharon Prince
Journal:  Cancers (Basel)       Date:  2020-02-21       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.